SCHEDULE: Anson Funds Discloses 5.7% Stake in Sellas Life Sciences
Beneficial Ownership Report
Anson Funds Management LP and affiliated entities have reported a 5.7% beneficial ownership stake in Sellas Life Sciences Group, Inc., totaling 6,032,938 shares.
Summary
- Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam (collectively "Anson Funds") have jointly filed a Schedule 13G.
- The filing reports beneficial ownership of 6,032,938 shares of Common Stock of Sellas Life Sciences Group, Inc.
- This represents 5.7% of the outstanding Common Stock of Sellas Life Sciences Group, Inc.
- The percentage is calculated based on 105,297,469 shares outstanding, as reported in the Issuer's Form 10-Q filed with the SEC on August 12, 2025.
- The shares are held by private funds for which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors.
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of beneficial ownership, indicating institutional interest in the company. While not directly commenting on company performance, a significant stake by an investment group can be viewed as a positive signal of investor confidence or strategic positioning.
Positives
- Significant institutional investment by Anson Funds, indicating confidence or strategic interest in Sellas Life Sciences Group, Inc.
Future Outlook
NA
Industry Context
This filing indicates a notable institutional investment in Sellas Life Sciences Group, Inc., a company operating in the life sciences sector. Such disclosures are common as investment funds accumulate significant stakes, reflecting their investment strategies within the industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially the stock price, signaling increased institutional interest.
Key Dates
| Date | Description |
|---|---|
| 2025-08-12 | Date of Issuer's Quarterly Report on Form 10-Q, which reported 105,297,469 shares outstanding. |
| 2025-09-30 | Date of event which requires the filing of this statement (beneficial ownership threshold met). |
| 2025-11-14 | Date of execution of the Joint Filing Agreement and filing of the Schedule 13G. |
Keywords
Sellas Life Sciences Group, Anson Funds Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.